Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study consists of two parts. Phase Ia is a dose escalation study to determine the
maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of MRG001. Phase Ib is a
dose expansion study to assess the preliminary efficacy of MRG001 in patients with
CD20-positive relapsed or refractory B-cell NHL at the confirmed RP2D. The safety,
tolerability, pharmacokinetic (PK) and immunogenicity of MRG001 will be evaluated in both
parts.